Most recent update: Friday, February 28, 2020 - 09:52

Bariatric News - Cookies & privacy policy

You are here Top 10 most read articles in June 2014

Just in case you missed any news last month, these were the 10 most read articles on in June 2014 including the latest research, product & industry news, policy news and more...

Study links Helicobacter pylori treatment to weight gain

People treated for the Helicobacter pylori infection developed significant weight gain compared to subjects with untreated H pylori colonisation, suggesting that treating the bacteria is linked to weight gain, according to research published in the journal Alimentary Pharmacology & Therapeutics…(more)

Depression linked to obesity, drugs linked to weight gain

Two studies have provided new insights into the issue surrounding depression, antidepressants and obesity. The first concludes that major depressive disorder (MDD) appears to be associated with obesity, whilst a second paper reports that some antidepressants can lead to weight gain among patients…(more)

Surgery reduces cancer rates but reasons unknown

Bariatric surgery induced weight loss can help reduce the risk of cancer to rates almost similar to those of people of normal weight, according to the findings of the first comprehensive review published in Obesity Surgery. The review, which takes into account relevant studies about obesity, cancer rates and bariatric surgery, concluded that the reasons for the findings were unknown but likely associated with weight loss or better awareness/diagnosis post-surgery…(more)

Nutritional guidance is essential post-surgery

The intake of macronutrients increases three months post-surgery but the micronutrient intake remains at a ‘worryingly low level’ and it is essential that nutritional guidance is provided to patients following bariatric surgery, according to researchers from Belgium...(more)

15-year SOS outcomes show surgical superiority

Bariatric surgery was associated with greater remission from diabetes and fewer complications than patients who received usual care, according the 15-year outcomes from the Swedish Obese Subjects (SOS) study. Published in JAMA, the reported diabetes remission rate two years after surgery was 16.4% (11.7%-22.2%; 34/207) for control patients and 72.3% (66.9%-77.2%; 219/303) for bariatric surgery patients (p<0.001). However, at 15 years, the diabetes remission rates decreased to 6.5% (4/62) for control patients and to 30.4% (35/115) for bariatric surgery patients (p<0.001)…(more)

Diet or surgery alters our perception of food

How we lose weight affects how our brains respond to images of food, according to brain imaging research conducted at the University of Kansas School of Medicine. The study, published in the journal Obesity, examined brain changes associated with different methods of weight loss…(more)

Surgery reduces adverse effects of obesity on QoL

Gastric bypass surgery improves obese diabetic patients' physical and mental health, more than an intensive weight loss programme involving lifestyle modifications over two years, according to the results from a study presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago…(more)

Leptin influences brain cells that control appetite

In addition to influencing neurons to help regulate metabolism, appetite, and weight Leptin also acts on other types of cells to control appetite, according to researchers from the Yale School of Medicine. The findings could lead to development of treatments for metabolic disorders…(more)

Medtronic to buy Covidien for US$42.9 billion

Medtronic has agreed to buy Dublin-based, Covidien, for US$42.9 billion (£25.27 billion) and shift its executive headquarters to Ireland. According to analysts, the cash and stock deal will allow Medtronic to reduce its overall global tax burden, which is currently 18 percent, although the company emphasised the acquisition led by a complementary strategy with Covidien on medical technology, rather than tax considerations…(more)

FDA recommends VBLOC vagal blocking therapy

The FDA Advisory Gastroenterology and Urology Devices Panel (GUDP) has voted eight to one in favour of EnteroMedics’ neuroblocking technology to treat obesity, the Maestro System. The Panel voted that the device is safe when used as designed and voted four to five against on the issue of a reasonable assurance of efficacy.  The final vote, on whether the relative benefits outweighed the relative risk, was six to two in favour, with one abstention...(more)